• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脱敏治疗后成功进行的人类白细胞抗原(HLA)与ABO血型不相容的第三次肾移植:一例报告及文献综述

Successful Third Kidney Transplant After Desensitization for Combined Human Leucocyte Antigen (HLA) and ABO Incompatibility: A Case Report and Review of Literature.

作者信息

Thukral Sharmila, Shinde Nikhil, Mukherjee Kaustuv, Ray Deepak Shankar

机构信息

Department of Nephrology and Transplant, Narayana Health Hospital, Mukundapur, West Bengal, India.

Department of Nephrology, Narayana Health Hospital, Mukundapur, West Bengal, India.

出版信息

Am J Case Rep. 2019 Mar 4;20:285-289. doi: 10.12659/AJCR.913690.

DOI:10.12659/AJCR.913690
PMID:30828083
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6410605/
Abstract

BACKGROUND In the present era, kidney transplantation across immunological barriers (ABO incompatibility and human leucocyte antigen (HLA) incompatibility) is a successful strategy to provide transplantation to immunologically high-risk patients. The safety and outcome of crossing both ABO and HLA barriers simultaneously in a retransplantation scenario is rarely reported from the developing world. CASE REPORT A 30-year-old female underwent a third living donor kidney transplantation. Her previous 2 transplants being lost to chronic allograft nephropathy. The transplantation was done across a simultaneous blood group as well as HLA incompatibility. The donor was the mother who was blood group B, with the recipient being blood group O. The complement dependent cytotoxicity crossmatch of the pair was negative but the flow cross match for T as well as B lymphocytes was positive. The mean fluorescence intensity value for class I antigens was 6951 and that for class 2 antigens was 7534. The patient underwent a desensitization procedure including rituximab, plasmapheresis and intravenous immunoglobulin pre-transplantation. The pre-transplantation isohemaglutunin titer was <1: 8 and the donor specific antibody against class 1 antigens was <2200 and <770 against class 2 antigens. Induction was done with anti-thymocyte globulin in the dose of 3 mg/kg in 2 divided doses. The patient is maintained on triple immunosuppression with tacrolimus, prednisolone and mycophenolate mofetil. After a follow-up period of 5 months, she maintains a good graft function with serum creatinine of 1.01 mg/dL. CONCLUSIONS With the advances in the desensitizing procedures in the developing world, kidney transplantation across a combined HLA and ABO incompatible barrier can be offered to these highly sensitized patients, even in case of retransplantation.

摘要

背景 在当今时代,跨越免疫屏障(ABO血型不相容和人类白细胞抗原(HLA)不相容)进行肾移植是为免疫高风险患者提供移植的成功策略。在发展中国家,关于在再次移植情况下同时跨越ABO和HLA屏障的安全性和结果鲜有报道。

病例报告 一名30岁女性接受了第三次活体供肾移植。她之前的2次移植均因慢性移植肾肾病而失败。此次移植是在血型和HLA均不相容的情况下进行的。供体是母亲,血型为B型,受体血型为O型。该配对的补体依赖细胞毒性交叉配型为阴性,但T淋巴细胞和B淋巴细胞的流式交叉配型为阳性。I类抗原的平均荧光强度值为6951,II类抗原的平均荧光强度值为7534。患者在移植前接受了包括利妥昔单抗、血浆置换和静脉注射免疫球蛋白在内的脱敏治疗。移植前的同种血凝素效价<1:8,针对I类抗原的供体特异性抗体<2200,针对II类抗原的供体特异性抗体<770。诱导治疗采用抗胸腺细胞球蛋白,剂量为3mg/kg,分2次给药。患者接受他克莫司、泼尼松龙和霉酚酸酯三联免疫抑制治疗。经过5个月的随访,她的移植肾功能良好,血清肌酐为1.01mg/dL。

结论 随着发展中国家脱敏程序的进展,即使在再次移植的情况下,也可以为这些高度致敏的患者提供跨越HLA和ABO联合不相容屏障的肾移植。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d724/6410605/bf40cd3addf9/amjcaserep-20-285-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d724/6410605/eb3620335a02/amjcaserep-20-285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d724/6410605/bf40cd3addf9/amjcaserep-20-285-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d724/6410605/eb3620335a02/amjcaserep-20-285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d724/6410605/bf40cd3addf9/amjcaserep-20-285-g002.jpg

相似文献

1
Successful Third Kidney Transplant After Desensitization for Combined Human Leucocyte Antigen (HLA) and ABO Incompatibility: A Case Report and Review of Literature.脱敏治疗后成功进行的人类白细胞抗原(HLA)与ABO血型不相容的第三次肾移植:一例报告及文献综述
Am J Case Rep. 2019 Mar 4;20:285-289. doi: 10.12659/AJCR.913690.
2
ABO-Incompatible Renal Transplantation with High Antibody Titer: A Case Report.高抗体滴度的ABO血型不相容肾移植:一例报告
Am J Case Rep. 2017 Oct 6;18:1073-1076. doi: 10.12659/ajcr.905633.
3
Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report.对具有高难治性和反弹抗血型抗体的ABO血型不相容亲属活体肾移植受者进行长期脱敏治疗:病例报告
BMC Nephrol. 2018 Oct 5;19(1):254. doi: 10.1186/s12882-018-1053-8.
4
Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.人类白细胞抗原及ABO血型不相容的活体供肾移植脱敏治疗结果:100余例患者的单中心经验
Transplant Proc. 2013 May;45(4):1423-6. doi: 10.1016/j.transproceed.2013.01.081.
5
Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.免疫高风险肾移植脱敏治疗的结果:单中心经验
Transplant Proc. 2019 Sep;51(7):2268-2273. doi: 10.1016/j.transproceed.2019.04.068. Epub 2019 Jul 26.
6
Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.利妥昔单抗联合双重滤过血浆置换的ABO血型不相容肾移植的临床结局
Exp Clin Transplant. 2014 Oct;12(5):401-4.
7
Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.ABO血型抗体不相容肾移植中的个体化脱敏策略
Transpl Int. 2014 Feb;27(2):187-96. doi: 10.1111/tri.12234. Epub 2013 Dec 28.
8
Successful desensitization and kidney transplantation in the presence of donor-specific anti-human leukocyte antigen antibodies in kidney transplant recipients.在接受肾移植的患者中存在供体特异性抗人类白细胞抗原抗体的情况下成功脱敏和肾移植。
Saudi J Kidney Dis Transpl. 2020 Nov-Dec;31(6):1432-1438. doi: 10.4103/1319-2442.308365.
9
Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy.采用血浆置换和抗CD20进行脱敏治疗以实现ABO血型不相容的活体供肾移植:意大利单中心经验
Transplant Proc. 2014 Sep;46(7):2209-13. doi: 10.1016/j.transproceed.2014.07.063.
10
Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.在移植前存在供体特异性抗体阳性和 CDC 交叉配型阴性的情况下,肾移植后 1 年内频繁发生亚临床慢性抗体介导的排斥反应。
Hum Immunol. 2013 Sep;74(9):1111-8. doi: 10.1016/j.humimm.2013.06.022. Epub 2013 Jun 18.

引用本文的文献

1
ABO-incompatible Repeat Kidney Transplantation: Coping with the 'Twin Immunological Barrier'.ABO血型不相容的重复肾移植:应对“双重免疫屏障”
Indian J Nephrol. 2022 Jan-Feb;32(1):82-86. doi: 10.4103/ijn.IJN_64_20. Epub 2022 Jan 5.

本文引用的文献

1
Kidney retransplantation from HLA-incompatible living donors: A single-center study of 3rd/4th transplants.来自HLA不相合活体供者的肾脏再次移植:一项关于第三次/第四次移植的单中心研究
Clin Transplant. 2017 Nov;31(11). doi: 10.1111/ctr.13104. Epub 2017 Oct 5.
2
The UK National Registry of ABO and HLA Antibody Incompatible Renal Transplantation: Pretransplant Factors Associated With Outcome in 879 Transplants.英国ABO和HLA抗体不相容肾移植国家登记处:879例移植中与结局相关的移植前因素。
Transplant Direct. 2017 Jun 26;3(7):e181. doi: 10.1097/TXD.0000000000000695. eCollection 2017 Jul.
3
Clinical outcomes of ABO- and HLA-incompatible kidney transplantation: a nationwide cohort study.
ABO 和 HLA 不相容的肾移植的临床结果:一项全国性队列研究。
Transpl Int. 2017 Dec;30(12):1215-1225. doi: 10.1111/tri.12979. Epub 2017 Jul 6.
4
Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.来自 HLA 不相合活体供者的肾移植的生存获益
N Engl J Med. 2016 Mar 10;374(10):940-50. doi: 10.1056/NEJMoa1508380.
5
Kidney retransplantation in the ipsilateral iliac fossa: a surgical challenge.同侧髂窝肾再移植:一项外科挑战。
Am J Transplant. 2015 Nov;15(11):2947-54. doi: 10.1111/ajt.13369. Epub 2015 Jul 7.
6
Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.高度人白细胞抗原致敏患者脱敏后移植的抗体介导排斥反应和移植物丢失的预测因素。
Transplantation. 2015 Jul;99(7):1423-30. doi: 10.1097/TP.0000000000000525.
7
Graft and patient survival outcomes of a third kidney transplant.第三次肾移植的移植物和患者生存结果。
Transplantation. 2015 Feb;99(2):416-23. doi: 10.1097/TP.0000000000000332.
8
ABO-incompatible kidney transplantation: long-term outcomes.ABO血型不相容肾移植:长期预后
Clin Transpl. 2013:307-12.
9
OPTN/SRTR 2012 Annual Data Report: kidney.器官获取与移植网络/器官共享联合网络2012年度数据报告:肾脏
Am J Transplant. 2014 Jan;14 Suppl 1:11-44. doi: 10.1111/ajt.12579.
10
Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.人类白细胞抗原及ABO血型不相容的活体供肾移植脱敏治疗结果:100余例患者的单中心经验
Transplant Proc. 2013 May;45(4):1423-6. doi: 10.1016/j.transproceed.2013.01.081.